Sign in

You're signed outSign in or to get full access.

Salvatore Caruso

Research Analyst at TD Cowen

Salvatore Caruso is a Research Analyst at TD Cowen, specializing in biotech equity research. He has covered specific companies including Puma Biotechnology, with documented activity such as asking questions on earnings calls, though detailed performance metrics like success rates or rankings on platforms such as TipRanks are not publicly available in current sources. Previously known as a Biotech Equity Research Associate at Cowen Inc., he is based in New York, with limited public details on exact career start dates or prior firms; professional credentials such as FINRA registrations are not specified in available profiles.

Salvatore Caruso's questions to Scholar Rock Holding (SRRK) leadership

Question · Q4 2025

Salvatore Caruso inquired about the status of the MAA review in Europe, specifically if the market would be served by the Catalent Indiana facility and if the EMA has responded to FDA inspection findings.

Answer

David Hallal, Chairman and Chief Executive Officer, explained that mutual recognition between FDA and EMA means FDA's progress supports the EMA review. Akshay Vaishnaw, President of R&D, added that the EMA is aware and supportive, awaiting resolution of the Catalent issues.

Ask follow-up questions

Fintool

Fintool can predict Scholar Rock Holding logo SRRK's earnings beat/miss a week before the call

Question · Q4 2025

Salvatore Caruso asked about the status of the MAA review in Europe, specifically if the market would be served by the Catalent Indiana facility and if the EMA has responded to the FDA's inspection findings.

Answer

David Hallal, Chairman and CEO of Scholar Rock, explained the mutual recognition between FDA and EMA, indicating that progress with the FDA positively impacts the MAA review. Akshay Vaishnaw, President of R&D, Scholar Rock, added that they have maintained close contact with the EMA, who are aware and supportive, awaiting the resolution of Catalent's issues.

Ask follow-up questions

Fintool

Fintool can write a report on Scholar Rock Holding logo SRRK's next earnings in your company's style and formatting

Salvatore Caruso's questions to PUMA BIOTECHNOLOGY (PBYI) leadership

Question · Q4 2025

Salvatore Caruso asked about the dynamics of the inventory build in the fourth quarter, its relation to previous quarters, any emerging overall trends, and future expectations regarding inventory.

Answer

CEO Alan Auerbach and CFO Maximo Nougues explained that an inventory build is typically observed at the end of the year, particularly in Q4, often driven by distributors anticipating price increases. They noted that this Q4 build usually burns off in Q1, a consistent trend observed over nine years of product launch.

Ask follow-up questions

Fintool

Fintool can predict PUMA BIOTECHNOLOGY logo PBYI's earnings beat/miss a week before the call

Question · Q4 2025

Salvatore Caruso with TD Cowen inquired about the dynamics of the inventory build observed in the fourth quarter, its relationship to previous quarters' builds, and any overarching trends or future expectations regarding inventory levels.

Answer

Alan Auerbach, Executive Chairman, President, and CEO of Puma Biotechnology, explained that a Q4 inventory build is a consistent trend since launch, often driven by anticipated price increases at the start of the new year. Maximo Nougues, CFO, added that this build typically leads to a burn-off in Q1, influencing lower Q1 guidance.

Ask follow-up questions

Fintool

Fintool can write a report on PUMA BIOTECHNOLOGY logo PBYI's next earnings in your company's style and formatting